Essex LLC’s Novartis NVS Stock Holding History

Essex LLC’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$235K	Sell	1,500 -950	-39%	-$142K	0.04%	163
2026 Q1	$374K	Hold	2,450	–	–	0.07%	133
2025 Q4	$338K	Hold	2,450	–	–	0.06%	136
2025 Q3	$314K	Hold	2,450	–	–	0.06%	140
2025 Q2	$296K	Hold	2,450	–	–	0.06%	139
2025 Q1	$273K	Hold	2,450	–	–	0.06%	140
2024 Q4	$238K	Hold	2,450	–	–	0.05%	151
2024 Q3	$282K	Hold	2,450	–	–	0.06%	137
2024 Q2	$261K	Buy	2,450 +100	+4%	+$10K	0.06%	140
2024 Q1	$227K	Hold	2,350	–	–	0.05%	139
2023 Q4	$237K	Hold	2,350	–	–	0.06%	140
2023 Q3	$239K	Hold	2,350	–	–	0.07%	143
2023 Q2	$237K	Hold	2,350	–	–	0.07%	132
2023 Q1	$213K	Hold	2,350	–	–	0.06%	145
2022 Q4	$213K	Buy	+2,350	New	+$198K	0.06%	145
2022 Q2	–	Sell	-2,350	Closed	-$206K	–	163
2022 Q1	$206K	Hold	2,350	–	–	0.06%	159
2021 Q4	$206K	Buy	+2,350	New	+$195K	0.06%	167

Other funds holding NVS

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Essex LLC's NVS Position: Q2 2026 in Review

Essex LLC reduced its Novartis (NVS) stake by 39% in Q2 2026, selling an estimated $142K and leaving 1,500 shares worth $235K. The position accounts for 0.04% of the portfolio, ranked #163.

Essex LLC first reported a position in NVS in Q4 2021 and has held it in 17 quarters since. The position peaked at $374K in Q1 2026. 1,617 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

Essex LLC held 1,500 shares of Novartis worth $235K as of Q2 2026.
Essex LLC sold 950 Novartis shares in Q2 2026, an estimated $142K.
Novartis made up 0.04% of Essex LLC's portfolio in Q2 2026, its #163 holding.
Essex LLC first reported a position in Novartis in Q4 2021 and has held it in 17 quarters since.
Essex LLC's Novartis position peaked at $374K in Q1 2026.
1,617 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Essex LLC's 13F filing for Q2 2026, filed 24 Jul 2026.